Drug intelligence / Profile preview

SMDG-PN

Development stage: Preclinical
Lead developer: SMDG
Modality: Small Molecules
Administration: Parenteral

Overview

SMDG-PN is a small molecule therapeutic candidate being developed by SM Discovery Group (SMDG) for the treatment of pediatric neurological disorders. The program is currently in the lead optimization phase of preclinical development. While the specific biological target and mechanism of action have not been publicly disclosed, the asset is part of SMDG's focus on discovering novel small molecules for high-unmet-need areas in neurology.

Beyond the preview

Go deeper on SMDG-PN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMDG-PN.

Explore the full profile